Jason H Karnes1, Yan Gong2, Meghan J Arwood2, John G Gums3, Karen L Hall4, Marian C Limacher4, Julie A Johnson3, Rhonda M Cooper-DeHoff5. 1. Vanderbilt University School of Medicine, Nashville, TN, United States. 2. University of Florida College of Pharmacy, Gainesville, FL, United States. 3. University of Florida College of Pharmacy, Gainesville, FL, United States; University of Florida College of Medicine, Gainesville, FL, United States. 4. University of Florida College of Medicine, Gainesville, FL, United States. 5. University of Florida College of Pharmacy, Gainesville, FL, United States; University of Florida College of Medicine, Gainesville, FL, United States. Electronic address: dehoff@cop.ufl.edu.
Abstract
AIMS: Thiazide diuretics are recommended as first line antihypertensive treatment, but may contribute to new onset diabetes. We aimed to describe change in fasting glucose (FG) during prolonged thiazide treatment in an observational setting. METHODS: We conducted an observational, non-randomized, open label, follow-up study of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) and PEAR-2 studies. We enrolled previous participants from the PEAR or PEAR-2 studies with at least 6 months of continuous treatment with either hydrochlorothiazide (HCTZ) or chlorthalidone. Linear regression was used to identify associations with changes in FG after prolonged thiazide and thiazide-like diuretic treatment. RESULTS: A total of 40 participants were included with a mean 29 (range 8-72) months of thiazide treatment. FG increased 6.5 (SD 13.0) mg/dL during short-term thiazide treatment and 3.6 (SD 15.3) mg/dL FG during prolonged thiazide treatment. Increased FG at follow-up was associated with longer thiazide treatment duration (β=0.34, p=0.008) and lower baseline FG (β=-0.46, p=0.02). β blocker treatment in combination with prolonged thiazide diuretic treatment was also associated with increased FG and increased 2-h glucose obtained from OGTT. CONCLUSIONS: Our results indicate that prolonged thiazide treatment duration is associated with increased FG and that overall glycemic status worsens when thiazide/thiazide-like diuretics are combined with β blockers.
AIMS: Thiazide diuretics are recommended as first line antihypertensive treatment, but may contribute to new onset diabetes. We aimed to describe change in fasting glucose (FG) during prolonged thiazide treatment in an observational setting. METHODS: We conducted an observational, non-randomized, open label, follow-up study of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) and PEAR-2 studies. We enrolled previous participants from the PEAR or PEAR-2 studies with at least 6 months of continuous treatment with either hydrochlorothiazide (HCTZ) or chlorthalidone. Linear regression was used to identify associations with changes in FG after prolonged thiazide and thiazide-like diuretic treatment. RESULTS: A total of 40 participants were included with a mean 29 (range 8-72) months of thiazide treatment. FG increased 6.5 (SD 13.0) mg/dL during short-term thiazide treatment and 3.6 (SD 15.3) mg/dL FG during prolonged thiazide treatment. Increased FG at follow-up was associated with longer thiazide treatment duration (β=0.34, p=0.008) and lower baseline FG (β=-0.46, p=0.02). β blocker treatment in combination with prolonged thiazide diuretic treatment was also associated with increased FG and increased 2-h glucose obtained from OGTT. CONCLUSIONS: Our results indicate that prolonged thiazide treatment duration is associated with increased FG and that overall glycemic status worsens when thiazide/thiazide-like diuretics are combined with β blockers.
Authors: Ajay K Gupta; Bjorn Dahlof; Joanna Dobson; Peter S Sever; Hans Wedel; N R Poulter Journal: Diabetes Care Date: 2008-01-30 Impact factor: 19.112
Authors: Amir Tirosh; Iris Shai; Dorit Tekes-Manova; Eran Israeli; David Pereg; Tzippora Shochat; Ilan Kochba; Assaf Rudich Journal: N Engl J Med Date: 2005-10-06 Impact factor: 91.245
Authors: Joshua I Barzilay; Barry R Davis; Jeffrey A Cutler; Sara L Pressel; Paul K Whelton; Jan Basile; Karen L Margolis; Stephen T Ong; Laurie S Sadler; John Summerson Journal: Arch Intern Med Date: 2006-11-13
Authors: Anke-Hilse Maitland-van der Zee; Stephen T Turner; Gary L Schwartz; Arlene B Chapman; Olaf H Klungel; Eric Boerwinkle Journal: Am J Hypertens Date: 2005-08 Impact factor: 2.689
Authors: Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella Journal: JAMA Date: 2003-05-14 Impact factor: 56.272
Authors: Sonal Singh; Caitrin W McDonough; Yan Gong; Wael A Alghamdi; Meghan J Arwood; Salma A Bargal; Leanne Dumeny; Wen-Yi Li; Mai Mehanna; Bradley Stockard; Guang Yang; Felipe A de Oliveira; Natalie C Fredette; Mohamed H Shahin; Kent R Bailey; Amber L Beitelshees; Eric Boerwinkle; Arlene B Chapman; John G Gums; Stephen T Turner; Rhonda M Cooper-DeHoff; Julie A Johnson Journal: J Am Heart Assoc Date: 2018-03-09 Impact factor: 5.501